drugset

drugset / Trial / NCT07530666

Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia

NCT07530666 ↗

Phase 1/2 Not yet recruiting 58 enrolled Dartsbio Pharmaceuticals Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia

Timeline

Start: 2026-04-30
Primary completion: 2027-10-30
Completion: 2028-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DS010	Unknown	—	Intravenous

Indications